RJA
IMNM icon

Raymond James & Associates’s Immunome IMNM Stock Holding History

Raymond James & Associates’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$155K Buy
+10,586
New +$150K ﹤0.01% 3701

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

Raymond James & Associates's IMNM Position: Q3 2024 in Review

Raymond James & Associates opened a new position in Immunome (IMNM) in Q3 2024: 10,586 shares worth $155K. The stake represents ﹤0.01% of the portfolio and ranks #3701 among its holdings.

115 funds tracked by Wall St. Rank hold IMNM as of Q3 2024.

  • Raymond James & Associates held 10,586 shares of Immunome worth $155K as of Q3 2024.
  • Immunome was a new Raymond James & Associates position in Q3 2024.
  • Immunome made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #3701 holding.
  • 115 funds tracked by Wall St. Rank held Immunome as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.